Notice2022-17990
Proposed Data Collection Submitted for Public Comment and Recommendations
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
August 22, 2022
Issuing agencies
Health and Human Services DepartmentCenters for Disease Control and Prevention
Abstract
The Centers for Disease Control and Prevention (CDC), as part of its continuing effort to reduce public burden and maximize the utility of government information, invites the general public and other federal agencies the opportunity to comment on an existing information collection, as required by the Paperwork Reduction Act of 1995. This notice invites comment on an existing information collection project titled WISEWOMAN National Program Evaluation. The goal of the study is to assess the implementation of the WISEWOMAN program under the current cooperative agreement and measure the effect of the program on individual, organizational, and community-level outcomes.
Full Text
<html>
<head>
<title>Federal Register, Volume 87 Issue 161 (Monday, August 22, 2022)</title>
</head>
<body><pre>
[Federal Register Volume 87, Number 161 (Monday, August 22, 2022)]
[Notices]
[Pages 51429-51430]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2022-17990]
[[Page 51429]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[60Day-22-1279; Docket No. CDC-2022-0093]
Proposed Data Collection Submitted for Public Comment and
Recommendations
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice with comment period.
-----------------------------------------------------------------------
SUMMARY: The Centers for Disease Control and Prevention (CDC), as part
of its continuing effort to reduce public burden and maximize the
utility of government information, invites the general public and other
federal agencies the opportunity to comment on an existing information
collection, as required by the Paperwork Reduction Act of 1995. This
notice invites comment on an existing information collection project
titled WISEWOMAN National Program Evaluation. The goal of the study is
to assess the implementation of the WISEWOMAN program under the current
cooperative agreement and measure the effect of the program on
individual, organizational, and community-level outcomes.
DATES: CDC must receive written comments on or before October 21, 2022.
ADDRESSES: You may submit comments, identified by Docket No. CDC-2022-
0093 by either of the following methods:
<bullet> Federal eRulemaking Portal: <a href="http://www.regulations.gov">www.regulations.gov</a>. Follow
the instructions for submitting comments.
<bullet> Mail: Jeffrey M. Zirger, Information Collection Review
Office, Centers for Disease Control and Prevention, 1600 Clifton Road
NE, MS H21-8, Atlanta, Georgia 30329.
Instructions: All submissions received must include the agency name
and Docket Number. CDC will post, without change, all relevant comments
to <a href="http://www.regulations.gov">www.regulations.gov</a>.
Please note: Submit all comments through the Federal eRulemaking
portal (<a href="http://www.regulations.gov">www.regulations.gov</a>) or by U.S. mail to the address listed
above.
FOR FURTHER INFORMATION CONTACT: To request more information on the
proposed project or to obtain a copy of the information collection plan
and instruments, contact Jeffrey M. Zirger, Information Collection
Review Office, Centers for Disease Control and Prevention, 1600 Clifton
Road, NE, MS H21-8, Atlanta, Georgia 30329; Telephone: 404-639-7118;
Email: <a href="/cdn-cgi/l/email-protection#0f60626d4f6c6b6c21686079"><span class="__cf_email__" data-cfemail="d9b6b4bb99babdbaf7beb6af">[email protected]</span></a>.
SUPPLEMENTARY INFORMATION: Under the Paperwork Reduction Act of 1995
(PRA) (44 U.S.C. 3501-3520), federal agencies must obtain approval from
the Office of Management and Budget (OMB) for each collection of
information they conduct or sponsor. In addition, the PRA also requires
federal agencies to provide a 60-day notice in the Federal Register
concerning each proposed collection of information, including each new
proposed collection, each proposed extension of existing collection of
information, and each reinstatement of previously approved information
collection before submitting the collection to the OMB for approval. To
comply with this requirement, we are publishing this notice of a
proposed data collection as described below.
The OMB is particularly interested in comments that will help:
1. Evaluate whether the proposed collection of information is
necessary for the proper performance of the functions of the agency,
including whether the information will have practical utility;
2. Evaluate the accuracy of the agency's estimate of the burden of
the proposed collection of information, including the validity of the
methodology and assumptions used;
3. Enhance the quality, utility, and clarity of the information to
be collected;
4. Minimize the burden of the collection of information on those
who are to respond, including through the use of appropriate automated,
electronic, mechanical, or other technological collection techniques or
other forms of information technology, e.g., permitting electronic
submissions of responses; and
5. Assess information collection costs.
Proposed Project
WISEWOMAN National Program Evaluation (OMB Control No. 0920-1279,
Exp. 12/31/2022)--Extension--National Center for Chronic Disease
Prevention and Health Promotion (NCCDPHP), Centers for Disease Control
and Prevention (CDC).
Background and Brief Description
The CDC has supported the WISEWOMAN (Well-Integrated Screening and
Evaluation for Women Across the Nation) program since 1995. The
WISEWOMAN program is designed to serve low-income women ages 40-64 who
have elevated risk factors for cardiovascular disease (CVD) and have no
health insurance, or are underinsured for medical and preventive care
services. Through the WISEWOMAN program, women have access to screening
services for selected CVD risk factors such as elevated blood
cholesterol, hypertension, and abnormal blood glucose levels; referrals
to heathy behavior support programs; and referrals to medical care.
WISEWOMAN participants must be co-enrolled in the CDC-sponsored
National Breast and Cervical Cancer Early Detection Program (NBCCEDP).
The WISEWOMAN program is administered through cooperative
agreements with state, territorial, or tribal health departments. Each
WISEWOMAN recipient submits to CDC an annual progress report that
describes program objectives and activities, and semi-annual data
reports (known as minimum data elements, or MDEs) on the screening,
assessment, and healthy behavior support services offered to women who
participate in the program. Participant-level MDE are de-identified
prior to transmission to CDC.
In 2018, CDC released the fifth funding opportunity announcement
(FOA) for the WISEWOMAN program (DP18-1816), which resulted in five-
year cooperative agreements with 24 state, territorial, and tribal
health departments, including six new and 18 continuing awardees from
the previous funding opportunity. Key program elements were retained
(e.g., provision of screening services, promotion of healthy lifestyle
behaviors, and linkage to healthy behavior support services and
community based resources), but a number of changes were incorporated
into the program at that time. The current FOA reflects increased
emphasis on three strategies to reduce CVD risk and support
hypertension control and management, including: (1) tracking and
monitoring clinical measures; (2) implementing team-based care; and (3)
linking community resources and clinical services to support care
coordination, self-management, and lifestyle change.
CDC seeks to conduct a multi-component evaluation to assess the
effectiveness of the program on individual, organizational, and
community-level outcomes. The in-depth assessment is designed to
complement the routine progress and MDE information already being
collected from WISEWOMAN program recipients. The data collection
focuses on obtaining qualitative and quantitative information at the
organizational and community levels about process and procedures
implemented, and barriers, facilitators, and other contextual factors
that affect program implementation and
[[Page 51430]]
participant outcomes. Data collection activities include a Program
Survey with all WISEWOMAN awardee programs, administered in the second
and fourth program years, and a one-time site visit to each recipient
spread across the three-year data collection effort. During site
visits, semi-structured interviews will be conducted with WISEWOMAN
staff members and staff at partner organizations, such as clinical
providers and community-based resource providers, who are positioned to
provide a variety of perspectives on program implementation.
OMB approval is requested for a one-year Extension. CDC requests
approval for an estimated 84 annual burden hours. Participation is
voluntary and there are no costs to respondents other than their time.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Number of Average burden
Type of respondents Form name Number of responses per per response Total burden
respondents respondent (in hours) (in hours)
----------------------------------------------------------------------------------------------------------------
WISEWOMAN Recipient Program survey.. 16 1 1 16
Administrators.
Site Visit 8 1 90/60 12
Discussion
Guide.
Innovation Site 2 1 45/60 2
Visit
Discussion
Guide.
Recipient partners............ Site Visit 16 1 1 16
Discussion
Guide.
Innovation Site 2 1 45/60 2
Visit
Discussion
Guide.
Healthy behavior support staff Site Visit 16 1 1 16
Discussion
Guide.
Innovation Site 2 1 45/60 2
Visit
Discussion
Guide.
Clinical providers............ Site Visit 16 1 1 16
Discussion
Guide.
Innovation Site 2 1 45/60 2
Visit
Discussion
Guide.
---------------------------------------------------------------
Total..................... ................ .............. .............. .............. 84
----------------------------------------------------------------------------------------------------------------
Jeffrey M. Zirger,
Lead, Information Collection Review Office, Office of Scientific
Integrity, Office of Science, Centers for Disease Control and
Prevention.
[FR Doc. 2022-17990 Filed 8-19-22; 8:45 am]
BILLING CODE 4163-18-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on August 22, 2022.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.